# Navigating the Pitfalls of Research Compliance Auditing



HCCA Research Compliance Annual Conference June 2023




- We have no conflicts of interest related to this presentation.
- The opinions expressed are our own and do not necessarily reflect the views of our employers, colleagues, or friends.
- The information, thoughts, and opinions provided here are not legal advice: consult your institution's legal, compliance, and other appropriate leaders and, at their discretion, your local Medicare Administrative Contractor (MAC), for any specific billing questions or issues.

Home of Florida's largest clinical cancer research unit One of only 52 **NCI** designated <mark>cancer centers</mark>

Established by the Florida legislature in 1981

Named after H. Lee Moffitt, former Florida speaker of the house



#### **×NCI Designated Comprehensive Cancer Center**

# Research

Moffitt's research focuses on cutting-edge discoveries that can be rapidly translated into improved diagnostic, preventive and therapeutic advances.

# \$339M+

**Global & Extramural Funding** 

**\$**588M+

State, Federal & Commercial Grants

- 1. Cancer Biology and Evolution
- 2. Cancer Epidemiology
- 3. Health Outcomes and Behavior
- 4. Immuno-Oncology
- 5. Molecular Medicine






# **Research Impact**

> 100 Observational protocols & > 27,000 observational accruals





600+ Active Interventional Trials

**40%** Overall Accruals to Investigator-initiated studies



# Future

Moffitt Cancer Center introduces "Speros FL," Its 775-acre Pasco County Global Innovation Center

Featuring 16 million square feet of lab, office, manufacturing and clinical space, with potential to add classrooms, teaching kitchens, health clubs and a performing arts center. "Speros" - a derivative of "Sperare," meaning "to hope" or "to look forward to"



### Moffitt Research Compliance

- Study Audits
- Research Misconduct
- Research Data Concerns
- Research Record Retention & Disposal
- Academic Collaboration – USF
- More!




- Research Operations
- Research Finance
- Office of Sponsored Research
- Clinical Trials Business Office
- Revenue Cycle
- Research Leadership

- Research Financial Audits
  - Study Start-up
  - Research Finance
  - Clinical Research Billing
  - Informed consent
     & subject injury
- Grants Management
  - Budgeting
  - Subawards
  - Cost allocation
- Education
- More!

#### **Moffitt Research Compliance Program**

CORE FUNCTION Policies Education Audits Guidance Requests

**Emerging Issues** 



#### COLLABORATIONS WITH OTHER INSTITUTIONAL DEPTS

Revenue Cycle Research Compliance Attorney Internal Audit Research Operations

- Research Leadership
- Clinical Trials Office
- Non-Therapeutics Research Office
- Research Finance & OSR
- Clinical Trials Business Office

#### OTHER REGULATORY COMPLIANCE

Research Misconduct Research Data Concerns Research Record Retention & Disposal Academic Collaboration - USF

#### CROSS-OVER WITH OTHER AREAS OF COMPLIANCE


Billing & Coding Privacy COI & Foreign Influence

# Audience Discussion



- How many of you conduct Research Regulatory Audits?
- How many of you conduct Research Finance/Clinical Research Billing Audits?
- How many of you conduct both types of audits?
- How many of you are new to research (less than 1 year)?
- How many of you have 10 or more employees that report to you?
- How many of you have between 2 & 9 employees?
- How many of you are the sole employee of the department?

### **Objectives**



Describe Challenges in Research Compliance Auditing

### THAT WORD...


### AUDIT





Challenges & Pitfalls to Successful Compliance Auditing

- Fearing the Audit
- Silos
- Lack of Communication
- Adherence to Good Clinical Practice
- FDA Inspection Readiness
- Clinical Research Billing Operations
- Lack of/Unclear Policies
- Lack of Institutional Compliance Support
- Staffing Issues
- Complex Processes/Procedures
- Competing Priorities
- Lack of Education/Training



### What more can you think of?



Areas of prior failure Auditor limitations (knowledge/access)

●→◆ ↓ ■←●

Follow the Data

Process start to finish Use uniform metrics/attributes



Expect the Unexpected

Unanticipated findings inform the most



### Avoiding Pitfalls with Preparation

- Define Success
  - Clarify Scope limitations
  - Expectations
    - Adherence to federal regulations
    - Understand institutional risk tolerance
    - Risk reduction
    - Institutional policy or procedure conformity
    - Decreased non-compliance



### Avoid Pitfalls by Planning

Q	



|--|

-0



#### Define the audit

Audit Type

Scope, population, date range, organization of the fieldwork, timeline

For Cause, Limited Scope, Full Scope

**Audit Focus** Type of Audit

SCOPE What are the attributes of the audit? Are they clear to

stakeholders?

Randomization

Find the population and then randomize based on selected criteria

15



Goals not clearly defined

Timelines

Difficulty measuring growth


What story does the data tell?

Are there actionable outcomes?


Will others understand the scope?

Delivery of findings

### Polling Question #1 What are the Top Challenges/Pitfalls that You Face?



### **Objectives**



### **Compliance Audits**

Identify/mitigate institutional risk and foster continuous improvement

Ensure appropriate oversight, accurate financial decisions, process improvement, & regulatory compliance Identify opportunities to educate individual study teams or departments & make overall institutional changes


# Goals of the Audit

- Identify the goal(s)
  - Testing controls (like classic Internal Audit)
  - Life of CRB
    - Identify cross-departmental process and communication gaps
  - For-cause
- Could be combination of goals
- Could be a risk assessment to level-set stratification
  - Never been audited
  - Significant institutional change
  - Corrective action controls post-change



# Scope of the Audit

- For-cause
- Issues identified during Risk assessment
- Never been audited
- Significant institutional change
- Corrective action controls post-change
- Post audit monitoring




# Opportunities to Avoid Pitfalls Through Collaboration

• Define true risk

Staffing Issues

- Audit Scope Focused audit vs. full scoped audit
- Collaboration with individual QA initiatives
- Extend CAPA due dates



# Opportunities to Avoid Pitfalls Through Collaboration







What Do You Do to Increase Institutional Compliance Support?




Opportunities to Avoid Pitfalls Through Collaboration – GCP & FDA Readiness

- Helpful Documents & Expectations
- Education
- Involve other stakeholders
- Collaborative review for FDA readiness

#### Collaboration Opportunity – Clinical Research Billing



#### First Participant Enrolled Reviews



DO THIS Before Claims Go Out!!!


# Additional Collaboration Strategies

- Meet Regularly with Teams to Walk through Scenarios
  - Clarity
  - Understanding
  - Teaching Moment
- Ask Questions
- Be Present and Available
- Provide Support
- Transparency
- Provide References and Resources
- Remind Stakeholders: Findings are not punitive from a compliance audit!




#### **Compliance Dept Collaborations**


GCP	RBC
Subjects given study assessments not approved by the sponsor	Billed to payer with incorrect coding; billed to sponsor; loss of revenue
Discrepancies in drug reconciliation	Incorrect quantity charged to payer or sponsor
Treating physician not listed, not recognized or compensated	Inappropriate allocation of funds
Wrong dates entered for screening tests and/or other study related assessments	Triggers billing that could go to wrong payer with incorrect coding; loss or revenue
Not certifying/documenting visits	Delays in Revenue Cycle Reviews, potential for incorrect billing and payers, increases risk of double billing
Tests not required for study that are done anyway	Incorrect billing; loss of revenue
Pregnancy test done on women of none childbearing potential, i.e. hysterectomy	Unnecessary service; not billable to Medicare
Discrepancies/unable to find drug administration start/stop	Sponsor paid items could get billed to a payer incorrectly
Items and services that are "confirmatory"	Imaging done to confirm tumor progression or response outside of recommendations in guidelines - could trigger incorrect billing
Identify items and services unnecessarily repeated to fit the protocol's screening or other windows	If a patient has had a procedure that is "just outside" the protocol window, not billable without sponsor approval (should be in the CTA)
Missing source documentation	Verification missing; incorrect billing
Using an unapproved or inaccurate ICF	Billing review inconsistencies leading to incorrect billing
Missed scans/procedures	Invoicing issues; incorrect billing; loss of revenue
DOA Log Discrepancy	Incorrect billing or funds transfers



# Foundations to Successful Auditing

Leadership Buy In/C Suite Suppor	<ul> <li>Needs to come from the top!</li> <li>Organizational culture</li> </ul>
Communication & Collaboration	
Written Policies & Procedures	<ul><li>Are they updated?</li><li>Who reviews them?</li></ul>
Training & Education	<ul> <li>Do staff know what to do?</li> <li>Who tracks training &amp; education?</li> </ul>
Enforcement	
Response & Corrective Actions	Periodic Reviews
Monitoring & Auditing	






Take **HOT** issues to compliance!


• Understand the problem & where

- it went wrong.
- How much improvement?
- How to implement change?
- When to implement change?
- How to measure the impact of change.
- What will be affected by change?



• Implement the change


- Identify those affected by change
- Solicit buy-in to ensure effective change



- Document & evaluate the change
- Was it enough?

#### **Examples:**

Seek input from end users for gaps in processes



- No improvement return to Plan and consider new options
- Improvement evaluate if enough and return to Plan if needed
- Solicit feedback
- Update documentation & training
- Sustain the gain Monitor & revisit improvement
- Benchmark/Trends/Metrics

#### Examples

Prospective or in real-time QA Retrospective QA

# Root Cause Examples – Clinical Research Billing

**Charge Post Error** – Token charge missing

**Order Error** – Billing designation listed on the research order form

**CA Error** – Procedures are missing that are identified in the protocol

**CTMS Build Error** – Procedures missing footnotes


**CTMS Data Entry Error** – Procedure occurrence date does not match the result date within the EMR

**Charge Review Error** – Improperly reversing a charge to bill research when listed as routine care on the CA

**HB Process Errors** – Identification that overnight scripts are failing within the HB system

**PB Process Errors** – Identification that automation of dx z00.6 is failing within the PB system

Charge Po Error	st	Order		CA Err	or	OnCore Build Error	OnCore Data Entry Error	Charge Review Error	HB Process Errors	PB Process Errors	Comment	
	-		•		-	-	-	-	-	-		Ŧ



#### Background

<b>1</b>
----------

Protocol requires "Total Bilirubin (Fractionated)."



The calendar team has noted that total bilirubin is part of the CMP.



The coverage analyst notes that the CMP is routine for this population.



The study team and PI reviews the coverage analysis and signs off.



After final approval, study goes live.


#### Situation

- The first subject reaches the visit requiring the Fractionated Total Bilirubin, the nurse coordinator orders a direct and indirect bilirubin in addition to the CMP.
- The billing team sees these charges and releases them as not research related because they were not identified on the CA, and the coordinator only certified total bilirubin.
- During an audit, it was identified as a finding that the additional bilirubin charges were ordered specifically to satisfy the protocol requirements. After reaching out to the lab, it was confirmed "fractionated" Bilirubin requires all 3 labs to satisfy protocol requirements.

# What went wrong?

- The calendar builder entered exactly what was in the time and events table without catching the "fractionated" part in the protocol.
- Study team and PI missed this line item during their review of the calendar/coverage analysis and signed off.
- The billing review team did not question the discrepancy of the charges vs. the research order and billed the charges as unrelated to research.

**Improvement:** Teams needed to do more comprehensive reviews up front and talk across departments.







Benchmark & Develop Metrics



Gabriella Neff, Research Compliance Officer Gabriella.Neff@moffitt.org



Dawn N. Pittinger, DBA, MBA-HA, CHRC, CCP, CHC Research Financial Compliance Officer <u>Dawn.Pittinger@moffitt.org</u> <u>https://www.linkedin.com/in/dr-dawn-n-l-pittinger-31824148</u>



